CRNX
Price
$32.37
Change
+$1.10 (+3.52%)
Updated
Apr 23 closing price
Capitalization
2.91B
14 days until earnings call
RARE
Price
$37.31
Change
+$1.40 (+3.90%)
Updated
Apr 23 closing price
Capitalization
3.37B
7 days until earnings call
Ad is loading...

CRNX vs RARE

Header iconCRNX vs RARE Comparison
Open Charts CRNX vs RAREBanner chart's image
Crinetics Pharmaceuticals
Price$32.37
Change+$1.10 (+3.52%)
Volume$1.55M
Capitalization2.91B
Ultragenyx Pharmaceutical
Price$37.31
Change+$1.40 (+3.90%)
Volume$966.18K
Capitalization3.37B
CRNX vs RARE Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. RARE commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and RARE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (CRNX: $32.38 vs. RARE: $37.31)
Brand notoriety: CRNX and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 141% vs. RARE: 112%
Market capitalization -- CRNX: $2.91B vs. RARE: $3.37B
CRNX [@Biotechnology] is valued at $2.91B. RARE’s [@Biotechnology] market capitalization is $3.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, CRNX is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 3 bearish.
  • RARE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both CRNX and RARE are a good buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а +9.47% price change this week, while RARE (@Biotechnology) price change was +6.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

CRNX is expected to report earnings on Aug 08, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.37B) has a higher market cap than CRNX($2.91B). RARE YTD gains are higher at: -11.314 vs. CRNX (-36.671). CRNX has higher annual earnings (EBITDA): -336.07M vs. RARE (-469M). CRNX has more cash in the bank: 1.35B vs. RARE (610M). RARE has less debt than CRNX: RARE (40.3M) vs CRNX (51.7M). RARE has higher revenues than CRNX: RARE (560M) vs CRNX (1.04M).
CRNXRARECRNX / RARE
Capitalization2.91B3.37B86%
EBITDA-336.07M-469M72%
Gain YTD-36.671-11.314324%
P/E RatioN/AN/A-
Revenue1.04M560M0%
Total Cash1.35B610M222%
Total Debt51.7M40.3M128%
FUNDAMENTALS RATINGS
CRNX vs RARE: Fundamental Ratings
CRNX
RARE
OUTLOOK RATING
1..100
5413
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
58100
SMR RATING
1..100
7698
PRICE GROWTH RATING
1..100
8379
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
14n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (74) in the Biotechnology industry is in the same range as CRNX (89) in the Pharmaceuticals Major industry. This means that RARE’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for RARE (100) in the Biotechnology industry. This means that CRNX’s stock grew somewhat faster than RARE’s over the last 12 months.

CRNX's SMR Rating (76) in the Pharmaceuticals Major industry is in the same range as RARE (98) in the Biotechnology industry. This means that CRNX’s stock grew similarly to RARE’s over the last 12 months.

RARE's Price Growth Rating (79) in the Biotechnology industry is in the same range as CRNX (83) in the Pharmaceuticals Major industry. This means that RARE’s stock grew similarly to CRNX’s over the last 12 months.

RARE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that RARE’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXRARE
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 17 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DIERX40.03N/A
N/A
BNY Mellon International Core Equity I
FLDGX12.59N/A
N/A
Meeder Dynamic Allocation Retail
LMNVX114.12N/A
N/A
ClearBridge Value I
LMCHX30.27N/A
N/A
Lord Abbett Mid Cap Stock R6
FIFAX24.78N/A
N/A
American Funds Income Fund of Amer F3